• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 25-NSE filed

    1/22/21 9:02:30 AM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PRVL alert in real time by email
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    UNITED STATES
    OMB APPROVAL
    OMB Number: 3235-0080
    Expires: March 31, 2018
    Estimated average burden
    hours per response: 1.7
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549
    FORM 25
    NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
    UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.
    Commission File Number 001-38939
    Issuer: Prevail Therapeutics Inc.
    Exchange: Nasdaq Stock Market LLC
    (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)
    Address: 430 East 29th Street
    Suite 940
    New York NEW YORK 10016
    Telephone number: (917) 336-9310
    (Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
    common stock
    (Description of class of securities)
    Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:
    17 CFR 240.12d2-2(a)(1)
    17 CFR 240.12d2-2(a)(2)
    17 CFR 240.12d2-2(a)(3)
    17 CFR 240.12d2-2(a)(4)
    Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. 1
    Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.
    Pursuant to the requirements fo the Securities Exchange Act of 1934, Nasdaq Stock Market LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.
    2021-01-22 By Tara Petta Director
    Date Name Title
    1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PRVL alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $PRVL

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PRVL
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Lilly Completes Acquisition of Prevail Therapeutics

    INDIANAPOLIS, Jan. 22, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery and development at Lilly, extending Lilly's research efforts through the creation of a gene therapy program that will be anchored by Prevail's portfolio of clinical-stage and preclinical neuroscience assets. "We are pleased to complete the acquisition of Prevail and establish a gene therapy program at Lilly that has the potential to deliver transformative treatments for patients with neurodegenerative diseases such as Parkinson's, Gaucher and demen

    1/22/21 8:55:00 AM ET
    $LLY
    $PRVL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Lilly Announces Agreement to Acquire Prevail Therapeutics

    INDIANAPOLIS and NEW YORK, Dec. 15, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Prevail Therapeutics Inc. (NASDAQ: PRVL) today announced a definitive agreement for Lilly to acquire Prevail for $22.50 per share in cash (or an aggregate of approximately $880 million) payable at closing plus one non-tradable contingent value right ("CVR") worth up to $4.00 per share in cash (or an aggregate of approximately $160 million), for a total consideration of up to $26.50 per share in cash (or an aggregate of approximately $1.040 billion). The CVR is payable (subject to certain terms and conditions) upon the first regulatory approval of a product from Prevail's pipeline as set forth in

    12/15/20 6:15:00 AM ET
    $LLY
    $PRVL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Prevail Therapeutics Announces First Patient Dosed in Phase 1/2 PROCLAIM Clinical Trial Evaluating PR006 for the Treatment of Frontotemporal Dementia Patients with GRN Mutations

    NEW YORK, Dec. 11, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the first patient has been dosed in the Phase 1/2 PROCLAIM clinical trial evaluating PR006, an investigational AAV9 gene therapy delivering the GRN gene, for the treatment of frontotemporal dementia patients with GRN mutations (FTD-GRN). “Dosing the first patient in our PROCLAIM clinical trial marks an important milestone in our efforts to advance a potentially disease-modifying treatment for patients with frontotemporal dementia with GRN mutations,”

    12/11/20 7:00:00 AM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PRVL
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Llc Advisors Orbimed

    4 - Prevail Therapeutics Inc. (0001714798) (Issuer)

    1/26/21 5:20:50 PM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4: Asa Abeliovich decreased ownership by 100% to 0 units

    4 - Prevail Therapeutics Inc. (0001714798) (Issuer)

    1/26/21 5:19:57 PM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form 4 filed by M Timothy Adams

    4 - Prevail Therapeutics Inc. (0001714798) (Issuer)

    1/26/21 5:18:50 PM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PRVL
    SEC Filings

    View All

    SEC Form 15-12B filed

    15-12B - Prevail Therapeutics Inc. (0001714798) (Filer)

    2/1/21 6:40:58 AM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G filed

    SC 13G - Prevail Therapeutics Inc. (0001714798) (Subject)

    1/29/21 4:15:39 PM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form EFFECT filed

    EFFECT - Prevail Therapeutics Inc. (0001714798) (Filer)

    1/27/21 12:15:18 AM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PRVL
    Financials

    Live finance-specific insights

    View All

    Lilly Completes Acquisition of Prevail Therapeutics

    INDIANAPOLIS, Jan. 22, 2021 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) today announced the successful completion of its acquisition of Prevail Therapeutics Inc. (NASDAQ: PRVL). The acquisition establishes a new modality for drug discovery and development at Lilly, extending Lilly's research efforts through the creation of a gene therapy program that will be anchored by Prevail's portfolio of clinical-stage and preclinical neuroscience assets. "We are pleased to complete the acquisition of Prevail and establish a gene therapy program at Lilly that has the potential to deliver transformative treatments for patients with neurodegenerative diseases such as Parkinson's, Gaucher and demen

    1/22/21 8:55:00 AM ET
    $LLY
    $PRVL
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    Prevail Therapeutics Receives European Commission Orphan Designation for PR006 for the Treatment of Frontotemporal Dementia

    NEW YORK, Nov. 30, 2020 (GLOBE NEWSWIRE) -- Prevail Therapeutics Inc. (Nasdaq: PRVL), a biotechnology company developing potentially disease-modifying AAV-based gene therapies for patients with neurodegenerative diseases, today announced that the European Commission has granted orphan designation for PR006 for the treatment of frontotemporal dementia (FTD). PR006 is an investigational AAV9 gene therapy delivering the GRN gene and is being developed as a potential therapy for patients with frontotemporal dementia with GRN mutations (FTD-GRN). “The European Commission’s decision to grant orphan designation for PR006 is an important step in helping to advance this potential therapeutic optio

    11/30/20 7:00:00 AM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $PRVL
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G/A filed

    SC 13G/A - Prevail Therapeutics Inc. (0001714798) (Subject)

    2/16/21 4:39:44 PM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Prevail Therapeutics Inc. (0001714798) (Subject)

    2/16/21 4:30:31 PM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    SEC Form SC 13G/A filed

    SC 13G/A - Prevail Therapeutics Inc. (0001714798) (Subject)

    2/12/21 4:19:03 PM ET
    $PRVL
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care